User contributions for Edzelco
Jump to navigation
Jump to search
10 February 2024
- 19:0519:05, 10 February 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 19:0519:05, 10 February 2024 diff hist +23 Oteseconazole No edit summary current
- 19:0419:04, 10 February 2024 diff hist +25,740 N Oteseconazole Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co..."
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label3.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label2.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA structure.png No edit summary current
- 18:4718:47, 10 February 2024 diff hist −18 User:Edzelco →Edzel Lorraine Co, DMD, MD
7 February 2024
- 00:4700:47, 7 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +44 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +25,546 N Lutetium (177Lu) vipivotide tetraxetan Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout..." current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto label.png No edit summary current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto structure.png No edit summary current
6 February 2024
- 00:5700:57, 6 February 2024 diff hist +35 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:5700:57, 6 February 2024 diff hist +33,106 N Nivolumab and relatlimab-rmbw Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im..." current
- 00:5600:56, 6 February 2024 diff hist 0 N File:Nivolumab and relatlimab-rmbw label.png No edit summary current
- 00:2600:26, 6 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:2300:23, 6 February 2024 diff hist −2 Ganaxolone No edit summary current
- 00:2300:23, 6 February 2024 diff hist +24,999 Ganaxolone No edit summary
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle carton.png No edit summary current
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle suspension label 50mg.png No edit summary current
- 00:2100:21, 6 February 2024 diff hist 0 N File:Ganaloxone structure.png No edit summary current
2 February 2024
- 15:4915:49, 2 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4915:49, 2 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4815:48, 2 February 2024 diff hist −2 Pacritinib No edit summary current
- 15:4715:47, 2 February 2024 diff hist +29,299 N Pacritinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi..."
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Bottle Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Carton Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib supply.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib structure.png No edit summary current
1 February 2024
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +15 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +22,285 Mitapivat No edit summary current
- 16:2316:23, 1 February 2024 diff hist −23,245 Mitapivat Blanked the page Tag: Blanking
- 16:2216:22, 1 February 2024 diff hist +1,030 Mitapivat Undo revision 1736932 by Edzelco (talk) Tag: Undo
- 16:2216:22, 1 February 2024 diff hist −1,030 Mitapivat No edit summary
- 16:2116:21, 1 February 2024 diff hist −16 Mitapivat No edit summary
- 16:2016:20, 1 February 2024 diff hist −36 Mitapivat No edit summary
- 16:1916:19, 1 February 2024 diff hist +461 Mitapivat Undo revision 1736928 by Edzelco (talk) Tag: Undo
- 16:1916:19, 1 February 2024 diff hist −461 Mitapivat No edit summary
- 16:1616:16, 1 February 2024 diff hist −4 Mitapivat No edit summary Tag: Manual revert
- 16:1616:16, 1 February 2024 diff hist +4 Mitapivat No edit summary
- 16:1416:14, 1 February 2024 diff hist −2 Mitapivat No edit summary Tag: Manual revert
- 16:1416:14, 1 February 2024 diff hist +2 Mitapivat No edit summary
- 16:1316:13, 1 February 2024 diff hist +23,297 N Mitapivat Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,..."
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg.png No edit summary current
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg tablet blister pack.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat structure.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat supply.png No edit summary current
- 15:4615:46, 1 February 2024 diff hist +21 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4615:46, 1 February 2024 diff hist +26,967 N Sutimlimab-jome Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥..." current
- 15:4415:44, 1 February 2024 diff hist 0 N File:Sutimlimab-jome packaging.png No edit summary current
- 15:3215:32, 1 February 2024 diff hist +20 User:Edzelco No edit summary
- 15:3115:31, 1 February 2024 diff hist +24,023 N Faricimab-svoa Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]..." current
- 15:0515:05, 1 February 2024 diff hist +32 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0515:05, 1 February 2024 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +25 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0115:01, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +22 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 14:5914:59, 1 February 2024 diff hist +18,438 N Tebentafusp-tebn Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most..." current
- 01:4901:49, 1 February 2024 diff hist +604 Abrocitinib No edit summary current
- 01:4601:46, 1 February 2024 diff hist +13,636 Abrocitinib No edit summary
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 200mg.png No edit summary current
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 100mg.png No edit summary current
- 01:4301:43, 1 February 2024 diff hist 0 N File:Abrocitinib 50mg.png No edit summary current
- 01:3901:39, 1 February 2024 diff hist 0 N File:Abrocitinib supply.png No edit summary current
- 01:3201:32, 1 February 2024 diff hist 0 N File:Abrocitinib.png No edit summary current
- 01:3101:31, 1 February 2024 diff hist +22,842 N Abrocitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS..."
- 01:0601:06, 1 February 2024 diff hist −279 Daridorexant No edit summary current
31 January 2024
- 21:1721:17, 31 January 2024 diff hist +31,199 N Daridorexant Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue..."
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 3.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 2.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 1.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effects of hepatic impairment and renal impairment on daridorexant PK.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effect of daridorexant on the PK of other compounds.png No edit summary current
- 21:0621:06, 31 January 2024 diff hist 0 N File:Effect of co-administered compounds on the PK of daridorexant.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 3.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 2.png No edit summary current
- 21:0021:00, 31 January 2024 diff hist 0 N File:Packaging 1.png No edit summary current
- 20:4920:49, 31 January 2024 diff hist 0 N File:Daridorexant.png No edit summary current
25 January 2024
- 00:2500:25, 25 January 2024 diff hist +5,566 N Orbifloxacin Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Orbifloxacin |aOrAn=a |drugClass=fluoroquinolone carboxylic acid derivatives |indicationType=treatment |indication=urinary tract infections (cystitis) in dogs caused by susceptible strains of <i>Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli</i> and <i>Enterococcus faecalis</i>. |adverseReactions=In a field study, when the tablet formulation of orbifloxacin..." current
- 00:1600:16, 25 January 2024 diff hist 0 N File:Orbifloxacin packaging.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension 2.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin structure.png No edit summary current
23 January 2024
- 14:2814:28, 23 January 2024 diff hist +30,972 N Ado-Trastuzumab Emtansine Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Ado-trastuzumab emtansine |aOrAn=a |drugClass=HER2-targeted antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=1.) patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: a.) Received prior therapy for metastatic disease, or b.) Developed disease recurrence during or wi..." current
- 14:2414:24, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine packaging 160mg.png No edit summary current
- 14:2214:22, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine packaging.png No edit summary current
- 14:1914:19, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine supply.png No edit summary current